Video

New Mechanism for Treatment of Schizophrenia

Author(s):

Stephen Brannan, MD

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on their additional data presentation from the ACNP.

To get a closer look at the Phase 2 EMERGENT-1 poster that was presented at ACNP, see here.

Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Related Videos
schizophrenia
sc
schizophrenia
clozapine
brain
cognition
clock
clozapine
steering wheel
schizophrenia
Related Content
pills
April 30th 2025

April in Review: Updates on the Psychiatric Treatment Pipeline

Leah Kuntz
Treating ‘Morally Objectionable’ Patients
September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD
pharmacist
April 16th 2025

Treating Schizophrenia: Bringing Together Pharmacists and Clinicians for Patient Care

Michael McGuire, PharmD
More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle
May 11th 2021

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

Anita H. Clayton, MD
pregnant
April 11th 2025

Examining a Case of Acute Late-Pregnancy Psychosis: How Best to Coordinate Care

Cecilia A. Westbrook, MD, PhD Meredith Spada, MD Elizabeth M. Hovis, MD Jacob Larkin, MD Alexandra Nicholas, MD Luke Swider, MD Jonathan Yadlosky, MD Joseph S. DeRenzo, MD Adam P. Dunmore, MD Jennifer L. Kloesz, MD, FAAP Linda Dudas, RNC, MSN, CNL John Silipigni, MSW, MBA Priya Gopalan, MD
bipolar disorder
April 7th 2025

Online Survey Reveals Clinicians’ Top Concerns in BDI, Schizophrenia Treatment

Grace Koennecke
© 2025 MJH Life Sciences

All rights reserved.